Skip to main content

Joan Genescà Ferrer

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Joan Genescà Ferrer

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Chief Liver Unit.
Clinical director of Digestive Diseases.
Professor of Medicine of the UAB.

Projects

Estudio longitudinal de la expresión génica diferencial de la alteración vascular esplácnica en el modelo experimental de hipertensión portal de rata. Papel de los mecanismos de angiogénesis

IP: Joan Genescà Ferrer
Collaborators: Antonio González Fernández, Maria Nieves Martell Pérez-Alcalde
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 83490
Reference: SAF2006-03714
Duration: 01/10/2006 - 30/09/2009

Ministerio de Ciencia

Utilización de la tecnología de alto rendimiento de microchips de DNA en ell estudio de la fisiopatología de la alteración vascular arterial de la hipertensión portal experimental

IP: Joan Genescà Ferrer
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13200
Reference: PRED/IR-HUVH/29/2004
Duration: 01/01/2005 - 31/12/2008

Virus de l´hepatitis C com factor de risc per desenvolupar una diabetes mellitus: estudi dels mecanismes etiopatogènics

IP: Cristina Hernández Pascual
Collaborators: Rafael Simó Canonge, Juan Ignacio Esteban Mur, Joan Genescà Ferrer
Funding agency: Fundació La Marató de TV3
Funding: 41036.17
Reference: TV3/992610
Duration: 01/01/2000 - 31/12/2002

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Alfonso Biarnes Suñe

Alfonso Biarnes Suñe

Reconstructive Surgery of the Locomotor System
Read more
Sara Martin Sastre

Sara Martin Sastre

Predoctoral researcher
Shock, Organ Dysfunction and Resuscitation
Read more
Martín Huerta García

Martín Huerta García

Read more
Gesualdina Busiello

Gesualdina Busiello

Predoctoral researcher
Neuroradiology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.